Drug Trial Radar · NCT06102824
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
252
Planned (sponsor's estimate)
Start
Oct 1, 2024
Primary completion
Jun 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Guangdong Provincial People's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- First Affiliated Hospital, Sun Yat-Sen University; Sun Yat-sen University; Shantou Central Hospital
- First posted
- Oct 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, multicenter, open-label, randomized controlled trial to compare the efficacy of organoid-guided treatment (OGT) to treatment of physician's choice (TPC) in previously treated, HER2-negative locally advanced or metastatic breast cancer. The study will seek to provide evidence for utilizing patient-derived organoid (PDO) model to personalize treatment strategies and inform clinical care for advanced breast cancer. Subjects randomized to the OGT group will undergo PDO generation and receive treatment dictated by subsequent PDO drug sensitivity screening. Subjects randomized to the TPC group will receive empirical therapy as selected by the treating physician.
Conditions
- HER2-negative Breast Cancer
- Advanced Breast Cancer
Interventions
Organoid-guided treatmentDrug
The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
TaxaneDrug
Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w
CapecitabineDrug
1000-1250mg/m2, PO, bid, days1-14, q3w
GemcitabineDrug
800-1200mg/m2, IV, days 1, 8, q3w
VinorelbineDrug
20-35mg/m2, IV, days 1 and 8, q3w
EribulinDrug
1.4mg/m2, IV, days 1 and 8, q3w
AnthracyclineDrug
Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w
CarboplatinDrug
Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w
UtideloneDrug
30mg/m2, IV, once per day on days 1-5, q3w
Trastuzumab deruxtecanDrug
5.4mg/kg, IV, q3w
Sacituzumab govitecanDrug
10mg/kg, IV, days 1 and 8, q3w
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: Through study completion, with an expected average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.